Online inquiry

IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10340MR)

This product GTTS-WQ10340MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL17A&TNFSF13B gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002190.3; NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605; 10673
UniProt ID Q16552; Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10340MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2034MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AHLX-20
GTTS-WQ4290MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB-054
GTTS-WQ11239MR IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MEDI3902
GTTS-WQ11963MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MM-005
GTTS-WQ12513MR IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA NOE-102
GTTS-WQ699MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA A-1230717
GTTS-WQ15116MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SYD985
GTTS-WQ15011MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SNDX-6352
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW